BioCentury on BioBusiness,
Product Discovery & Development
Alkermes advancing new trial design to eliminate placebo problems in depression
Related tables, figures and sidebars
New designs in depression
Monday, November 18, 2013
An innovative clinical trial design developed by a pair of
academics is helping drug companies eliminate the placebo response that has
dogged development of drugs for depression. Next year, Alkermes
plc will become the first sponsor to see whether a sequential parallel
comparison design can replicate a Phase II success in a Phase III trial.
In October, Alkermes received
Fast Track designation for ALKS 5461 as an adjunctive therapy to treat major
depressive disorder (MDD) and said it would begin a Phase III study in 2014
using sequential parallel comparison design (SPCD).
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2014 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]